Metotrexato en la artritis crónica por chikungunya
DOI:
https://doi.org/10.18041/2390-0512/biociencias.1.10598Palabras clave:
Chikungunya, artritis crónica, metrotexate, artritis reumatoideResumen
La enfermedad por chikungunya se caracteriza por ser una patología zoonótica que genera una incapacidad considerable en los seres humanos, debilitando su salud y estado físico. La artropatía por chikungunya ha demostrado que genera un compromiso funcional, emocional y de calidad de vida en las distintas poblaciones afectadas. A la fecha no existe consenso unificado para el tratamiento exitoso de la artritis crónica por chikungunya. Se han utilizado diversos esquemas de tratamiento, pero aún sin un respaldo de investigaciones clínicas integrales. Existen estudios clínicos en los cuales sugieren la eficacia del metrotexate en la artritis crónica por chikungunya, sin embargo, a la fecha aún no se han realizado ensayos clínicos aleatorizados con placebo en donde además de comprobar su eficacia, se evalúe su seguridad.
Descargas
Referencias
Vairo F, Haider N, Kock R, Ntoumi F, Ippolito G, Zumla A. Chikungunya: Epidemiology, Pathogenesis, Clinical Features, Management, and Prevention. Infect Dis Clin North Am. 2019;33(4):1003–25.
Bautista-Reyes E, Núñez-Avellaneda D, Alonso-Palomares LA, Salazar MI. Chikungunya: Molecular aspects, clinical outcomes and pathogenesis. Vol. 69, Revista de Investigacion Clinica. Instituto Nacional de la Nutricion Salvador Zubiran; 2017. p. 299–307.
Baxter VK, Heise MT. Immunopathogenesis of alphaviruses. In 2020. p. 315–82.
Luis Arredondo García J. Arbovirus en Latinoamérica Correspondencia [Internet]. Vol. 37. 2016. Available from: www.actapediatrica.org.mx
RS R, Suresh MM, Saini P, PM A, Sukumaran M, S C, et al. Clinical and virological characteristics of patients during the outbreak of chikungunya in Thiruvananthapuram, Kerala, India, 2019-2020. Journal of Clinical Virology Plus [Internet]. 2021;1(4):100043. Available from: https://doi.org/10.1016/j.jcvp.2021.100043
Jaller Raad J, Sánchez Rincones W, Santrich Martínez A, Sierra Hernández A, Fonseca Estrada Y, Parody A, et al. Caracterización clínica de sujetos infectados con virus chikungunya, en una población del Caribe colombiano. Revista Colombiana de Reumatología. 2016;23(3):170–6.
Rodríguez-Morales AJ, Cardona-Ospina JA, Fernanda Urbano-Garzón S, Sebastian Hurtado-Zapata J. Prevalence of Post-Chikungunya Infection Chronic Inflammatory Arthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2016 Dec 1;68(12):1849–58.
Palacios-Martínez D, Díaz-Alonso RA, Arce-Segura LJ, Díaz-Vera E. Chikungunya, una enfermedad vírica emergente. Propuesta de un algoritmo de manejo clínico. Semergen. 2015;41(4):221–5.
Suhrbier A. Rheumatic manifestations of chikungunya: emerging concepts and interventions. Nat Rev Rheumatol [Internet]. 2019;15(10):597–611. Available from: http://dx.doi.org/10.1038/s41584-019-0276-9
Rodriguez-Morales AJ, Cardona-Ospina JA, Villamil-Gómez W, Paniz-Mondolfi AE. How many patients with post-chikungunya chronic inflammatory rheumatism can we expect in the new endemic areas of Latin America? Rheumatol Int. 2015 Dec 5;35(12):2091–4.
Ghauri MI, Mukarram MS, Kumar A, Riaz A, Riaz U, Iqbal M. Post Chikungunya Arthritis: A Real Diagnostic and Therapeutic Challenge. J Dow Univ Health Sci. 2020 Apr 29;14(1):22–6.
Abella J, Rojas Á, Rojas C, Rondón F, Medina Y, Peña M, et al. Clinical and immunological features of post-chikungunya chronic arthritis and its effect on functional ability and quality of life in a cohort of Colombian patients. Revista Colombiana de Reumatologia. 2019;26(4):255–61.
Poon AN, Simon GL, Chang AY. Treatment of Chronic Chikungunya With Methotrexate. JCR: Journal of Clinical Rheumatology [Internet]. 2021 Dec;27(8S):S563–4. Available from: https://journals.lww.com/10.1097/RHU.0000000000000998
Adarsh MB, Sharma SK, Dwivedi P, Singh MP, Dhir V, Jain S. Methotrexate in Early Chikungunya Arthritis: A 6 Month Randomized Controlled Open-label Trial. Curr Rheumatol Rev. 2020 Dec 24;16(4):319–23.
Pitt Gameiro Sales GM, Crystine Pereira Barbosa I, Sampaio Canejo Neta M, Lopes De Melo P, de Azevedo Leitão R, de Albuquerque Melo M. Treatment of chikungunya chronic arthritis. Rev Assoc Med Bras. 2018;64(1):63.
Brito CAA de, Sohsten AKA von, Leitão CC de S, Brito R de CCM de, Valadares LDDA, Fonte CAM da, et al. Pharmacologic management of pain in patients with Chikungunya: a guideline. Rev Soc Bras Med Trop. 2016 Dec;49(6):668–79.
O’Driscoll M, Salje H, Chang AY, Watson H. Arthralgia resolution rate following chikungunya virus infection. International Journal of Infectious Diseases. 2021 Nov;112:1–7.
Peters CMM, Pijnacker R, Fanoy E, Bouwman LJT, de Langen L, van den Kerkhof JHTC, et al. Chikungunya virus outbreak in Sint Maarten: Long-term arthralgia after a 15-month period. J Vector Borne Dis. 2018;55(2):137.
Noor FM, Hossain MB, Islam QT. Prevalence of and risk factors for long-term disabilities following chikungunya virus disease: A meta-analysis. Travel Med Infect Dis. 2020 May;35:101618.
Jaffar-Bandjee MC, Ramful D, Gauzere BA, Hoarau JJ, Krejbich-Trotot P, Robin S, et al. Emergence and clinical insights into the pathology of Chikungunya virus infection. Vol. 8, Expert Review of Anti-Infective Therapy. 2010. p. 987–96.
McCarthy MK, Davenport BJJ, Morrison TE. Chronic Chikungunya Virus Disease. In 2018.
Chang AY, Martins KAO, Encinales L, Reid SP, Acuña M, Encinales C, et al. Chikungunya Arthritis Mechanisms in the Americas: A Cross-Sectional Analysis of Chikungunya Arthritis Patients Twenty-Two Months After Infection Demonstrating No Detectable Viral Persistence in Synovial Fluid. Arthritis and Rheumatology. 2018;70(4):585–93.
Amaral JK, Bingham CO, Schoen RT. Successful Methotrexate Treatment of Chronic Chikungunya Arthritis. JCR: Journal of Clinical Rheumatology. 2020 Apr;26(3):119–24.
Benjamanukul S, Osiri M, Chansaenroj J, Chirathaworn C, Poovorawan Y. Rheumatic manifestations of Chikungunya virus infection: Prevalence, patterns, and enthesitis. PLoS One. 2021 Apr 22;16(4):e0249867.
Pinto B, Desai A, Furruqh F, Sangeeta K, Charles B, Raj J, et al. US7 score in the subacute phase does not correlate with outcomes in Chikungunya arthritis. Indian J Rheumatol. 2021 Jun 1;16(2):204–8.
Chang AY, Encinales L, Porras A, Pacheco N, Reid SP, Martins KAO, et al. Frequency of Chronic Joint Pain Following Chikungunya Virus Infection: A Colombian Cohort Study. Arthritis and Rheumatology. 2018;70(4):578–84.
Murillo-Zamora E, Mendoza-Cano O, Trujillo-Hernández B, Guzmán-Esquivel J, Higareda-Almaraz E, Higareda-Almaraz MA, et al. Persistent Arthralgia and Related Risks Factors: A Cohort Study at 12 Months from Laboratory-Confirmed Chikungunya Infection. Arch Med Res. 2018 Jan;49(1):65–73.
Tritsch SR, Encinales L, Pacheco N, Cadena A, Cure C, McMahon E, et al. Chronic Joint Pain 3 Years after Chikungunya Virus Infection Largely Characterized by Relapsing-remitting Symptoms. J Rheumatol. 2020 Aug 1;47(8):1267–74.
Medina-Cintrón N, Martínez I, Pérez-Ríos N, Berríos-López Y, Vilá LM. Clinical Manifestations and Outcomes in Disease-Modifying Antirheumatic Drug-Naive Adult Patients with Chronic Chikungunya Arthritis. Am J Trop Med Hyg. 2021 May 5;104(5):1741–6.
Ali Ou Alla S, Combe B. Arthritis after infection with Chikungunya virus. Vol. 25, Best Practice and Research: Clinical Rheumatology. Bailliere Tindall Ltd; 2011. p. 337–46.
Tanay A. Chikungunya virus and autoimmunity. Curr Opin Rheumatol. 2017 Jul;29(4):389–93.
Heath CJ, Lowther J, Noël TP, Mark-George I, Boothroyd DB, Mitchell G, et al. The Identification of Risk Factors for Chronic Chikungunya Arthralgia in Grenada, West Indies: A Cross-Sectional Cohort Study. Open Forum Infect Dis. 2018 Jan 1;5(1).
Hossain S, Choudhury MR, Islam MdA, Hassan MdM, Yeasmin S, Hossain F, et al. Post-chikungunya arthritis: a longitudinal study in a tertiary care hospital in Bangladesh. Trop Med Health. 2022 Dec 8;50(1):21.
van Aalst M, Nelen CM, Goorhuis A, Stijnis C, Grobusch MP. Long-term sequelae of chikungunya virus disease: A systematic review. Travel Med Infect Dis. 2017 Jan;15:8–22.
Ninla-Aesong P, Mitarnun W, Noipha K. Proinflammatory Cytokines and Chemokines as Biomarkers of Persistent Arthralgia and Severe Disease after Chikungunya Virus Infection: A 5-Year Follow-Up Study in Southern Thailand. Viral Immunol. 2019 Dec 1;32(10):442–52.
Carvalho JF, Cordeiro LR, Silva FF, Mota L, Rodrigues C, Andrade CF, et al. Profile of several autoantibodies, complement and vitamin d levels in brazilian patients with chikungunya infection. Russian Journal of Infection and Immunity. 2021;11(5):979–83.
Bonifay T, Lienne JF, Bagoée C, Santa F, Vesin G, Walter G, et al. Prevalence and risk factors of post chikungunya rheumatic musculoskeletal disorders: a prospective follow-up study in French Guiana. European Journal of Clinical Microbiology & Infectious Diseases. 2018 Nov 17;37(11):2159–64.
Martínez Yoldi MJ, Sánchez-Seco Fariñas MP, Pérez Ruiz M, Vázquez González A. Diagnóstico microbiológico de las principales arbovirosis importadas y autóctonas. Vol. 68. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica ; 2020.
Sutaria RB, Amaral JK, Schoen RT. Emergence and treatment of chikungunya arthritis. Vol. 30, Current Opinion in Rheumatology. Lippincott Williams and Wilkins; 2018. p. 256–63.
Battisti V, Urban E, Langer T. Antivirals against the chikungunya virus. Vol. 13, Viruses. MDPI; 2021.
Alam H, Umer TP, Khanum I, Nazir L, Erum U, Irfan M. COMPARISON OF STEROIDS TO NSAIDS, AND OTHER FORMS OF ANALGESIA IN THE MANAGEMENT OF POST-CHIKUNGUNYA ARTHRITIS. PAFMJ. 2021 Apr 29;71(2):619–24.
Guaraldo L, Wakimoto MD, Ferreira H, Bressan C, Calvet GA, Pinheiro GC, et al. Treatment of chikungunya musculoskeletal disorders: a systematic review. Vol. 16, Expert Review of Anti-Infective Therapy. Taylor and Francis Ltd; 2018. p. 333–44.
Mahalingam S, Tharmarajah K, Zaid A. Chikungunya: Vaccines and therapeutics. Vol. 6, F1000Research. Faculty of 1000 Ltd; 2017.
Powers AM. Vaccine and therapeutic options to control chikungunya virus. Vol. 31, Clinical Microbiology Reviews. American Society for Microbiology; 2018.
Candidate S shot CV. Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate. 2022;6–8.
Zaid A, Gérardin P, Taylor A, Mostafavi H, Malvy D, Mahalingam S. Review: Chikungunya Arthritis: Implications of Acute and Chronic Inflammation Mechanisms on Disease Management. Arthritis & Rheumatology. 2018 Apr;70(4):484–95.
Javelle E, Ribera A, Degasne I, Gaüzère BA, Marimoutou C, Simon F. Specific Management of Post-Chikungunya Rheumatic Disorders: A Retrospective Study of 159 Cases in Reunion Island from 2006-2012. PLoS Negl Trop Dis. 2015 Mar 11;9(3).
Javelle E, Ribera A, Degasne I, Marimoutou C, Simon F. Clinical spectrum of post-chikungunya rheumatic musculoskeletal disorders and use of disease-modifying antirheumatic drugs to treat the chronic inflammatory entities: 6-year experience from Reunion Island. BMC Infect Dis. 2014 May;14(S2).
Bedoui Y, Giry C, Jaffar-Bandjee MC, Selambarom J, Guiraud P, Gasque P. Immunomodulatory drug methotrexate used to treat patients with chronic inflammatory rheumatisms post-chikungunya does not impair the synovial antiviral and bone repair responses. PLoS Negl Trop Dis. 2018 Aug 1;12(8).
Amaral J, Taylor P, Teixeira M, Morrison T, Schoen R. The Clinical Features, Pathogenesis and Methotrexate Therapy of Chronic Chikungunya Arthritis. Viruses. 2019 Mar 22;11(3):289.
Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. The Lancet. 2002 Apr;359(9313):1173–7.
Zhang X, Miao M, Zhang R, Liu X, Zhao X, Shao M, et al. Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther. 2022 Dec 7;7(1):67.
Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine [Internet]. 2019;86(3):301–7. Available from: https://doi.org/10.1016/j.jbspin.2018.07.004
Wood GS, Wu J. Methotrexate and Pralatrexate. Dermatol Clin [Internet]. 2015;33(4):747–55. Available from: http://dx.doi.org/10.1016/j.det.2015.05.009
Wessels JAM, Huizinga TWJ, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Vol. 47, Rheumatology. 2008. p. 249–55.
Montesinos MC, Yap JS, Desai A, Posadas I, Mccrary CT, Cronstein BN. REVERSAL OF THE ANTIINFLAMMATORY EFFECTS OF METHOTREXATE BY THE NONSELECTIVE ADENOSINE RECEPTOR ANTAGONISTS THEOPHYLLINE AND CAFFEINE Evidence that the Antiinflammatory Effects of Methotrexate are Mediated Via Multiple Adenosine Receptors in Rat Adjuvant Arthritis. Vol. 43, ARTHRITIS & RHEUMATISM. 2000.
Constantin A, Loubet-Lescouli� P, Lambert N, Yassine-Diab B, Abbal M, Mazi�res B, et al. Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: Evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis Rheum. 1998 Jan;41(1):48–57.
Dolhain RJ, Tak PP, Dijkmans BA, de Kuiper P, Breedveld FC, Miltenburg AM. Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Rheumatology. 1998 May 1;37(5):502–8.
Aringazina R, Myasoutova L, Babaskina L, Pashanova O. Correlation of pharmacokinetic dispositionof methotrexate and serum cytokine levels in rheumatoid arthritis patients. Bangladesh Journal of Medical Science. 2022 Feb 25;21(2):335–43.
Park JS, Lee D, Yang S, Jeong HY, Na HS, Cho KH, et al. Methotrexate-loaded nanoparticles ameliorate experimental model of autoimmune arthritis by regulating the balance of interleukin-17-producing T cells and regulatory T cells. J Transl Med. 2022 Dec 11;20(1):85.
Cronstein BN. Going with the flow: methotrexate, adenosine, and blood flow. Ann Rheum Dis. 2006 Apr 1;65(4):421–2.
Ochaion A, Bar-Yehuda S, Cohn S, del Valle L, Perez-Liz G, Madi L, et al. Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3adenosine receptor expression. Arthritis Res Ther [Internet]. 2006;8(6):R169. Available from: https://doi.org/10.1186/ar2078
Srimadh Bhagavatham SK, Potikuri D, Sivaramakrishnan V. Adenosine deaminase and cytokines associated with infectious diseases as risk factors for inflammatory arthritis and methotrexate as a potential prophylactic agent. Med Hypotheses. 2022 Feb;159:110751.
Bannwarth B, Labat L, Moride Y, Schaeverbeke T. Methotrexate in Rheumatoid Arthritis. Drugs. 1994 Jan;47(1):25–50.
Martí-Carvajal A, Ramon-Pardo P, Javelle E, Simon F, Aldighieri S, Horvath H, et al. Interventions for treating patients with chikungunya virus infection-related rheumatic and musculoskeletal disorders: A systematic review. PLoS One. 2017 Jun 13;12(6):e0179028.
Amaral JK, Sutaria R, Schoen RT. Treatment of Chronic Chikungunya Arthritis With Methotrexate: A Systematic Review. Arthritis Care Res (Hoboken). 2018 Oct;70(10):1501–8.
Publicado
Número
Sección
Licencia
Derechos de autor 2023 Biociencias
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
-
Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios<. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
-
NoComercial — No puede utilizar el material para una finalidad comercial.
-
CompartirIgual — Si remezcla, transforma o crea a partir del material, deberá difundir sus contribuciones bajo la misma licencia que el original.
- No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.
